"総合病院"

During the past decade, Japanese Red Cross Saitama Hospital conducted 11 clinical trials. In the 10-year time frame, 11 clinical trials started and 1 clinical trials were completed, i.e. on average, 9.1% percent of trials that started reached the finish line to date. In the past 5 years, 6 clinical trials started and 1 clinical trials were completed. i.e. 16.7% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Japanese Red Cross Saitama Hospital" #1 sponsor was "Bayer" with 2 trials, followed by "Chugai Pharmaceutical" with 2 trials sponsored, "AstraZeneca" with 1 trials sponsored, "Boston Scientific Corporation" with 1 trials sponsored and "Eli Lilly and Company" with 1 trials sponsored. Other sponsors include -1 different institutions and companies that sponsored additional 9 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Japanese Red Cross Saitama Hospital" #1 collaborator was "Japan Lung Cancer Society" with 2 trials as a collaborator, "Boehringer Ingelheim" with 1 trials as a collaborator, "ICON Clinical Research" with 1 trials as a collaborator, "Medtronic" with 1 trials as a collaborator and "Medtronic Japan Co., Ltd." with 1 trials as a collaborator. Other collaborators include -4 different institutions and companies that were collaborators in the rest 6 trials.

According to Clinical.Site data, the most researched conditions in "Japanese Red Cross Saitama Hospital" are "Heart Failure" (2 trials), "Arrhythmias, Cardiac" (1 trials), "Asthma" (1 trials), "Atrial Fibrillation" (1 trials) and "Autoimmune Pulmonary Alveolar Proteinosis" (1 trials). Many other conditions were trialed in "Japanese Red Cross Saitama Hospital" in a lesser frequency.

Most popular intervention types in "Japanese Red Cross Saitama Hospital" are "Drug" (4 trials), "Device" (2 trials) and "Other" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (2 trials), "Aflibercept High Dose VEGF Trap-Eye (BAY86-5321)" (1 trials), "Aflibercept VEGF Trap-Eye (Eylea, BAY86-5321)" (1 trials), "Anastrozole" (1 trials) and "CRT-D" (1 trials). Other intervention names were less common.

The vast majority of trials in "Japanese Red Cross Saitama Hospital" are 11 trials for "All" genders.

Currently, there are NaN active trials in "Japanese Red Cross Saitama Hospital". undefined are not yet recruiting, 5 are recruiting, 3 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 3 completed trials in Japanese Red Cross Saitama Hospital, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Japanese Red Cross Saitama Hospital, 0 "Phase 1" clinical trials were conducted, 0 "Phase 2" clinical trials and 4 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 1 trials that are defined as “Not Applicable".